Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Nektar Therapeutics Stock Fell as Much as 11.6% Today

By Maxx Chatsko - Oct 8, 2019 at 1:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst downgrade is only adding to the company's woes.

What happened

Shares of Nektar Therapeutics (NKTR -4.47%) fell over 11% today after the company was downgraded by a major investment bank. Goldman Sachs analyst Paul Choi played the role of heartbreaker by downgrading multiple pharmaceutical stocks, including Puma Biotechnology and Nektar Therapeutics. 

Choi cut his price target for Nektar Therapeutics from $54 to just $16 per share after bluntly stating that recent manufacturing discrepancies for bempegaldesleukin (bempeg) have overshadowed mostly positive clinical results released since the beginning of the year. Considering shares have plummeted 68% in the past year, investors can't really argue with that.

As of 12:36 p.m. EDT, the stock had settled to a 11.4% loss.

A finger tracing a declining stock chart on a display.

Image source: Getty Images.

So what

In August, Nektar Therapeutics disclosed that it had found manufacturing problems in two batches of bempeg that were used in early-stage clinical trials for the drug candidate. None of the manufactured product is being used in ongoing clinical trials, but the discovery of issues did delay development for a combination therapy with Opdivo from Bristol-Myers Squibb. It appears that the two batches of bempeg in question were not as potent as they should have been, although no differences in safety were observed.

Investors were originally worried that Bristol-Myers Squibb could walk away from the collaboration, but the pharma giant paid a significant sum of money to study bempeg. A decision on whether to commit to additional studies using the bempeg-Opdivo combination is expected this month.

That said, Choi's note hinged more on souring investor sentiment and updating his position from December 2018 than pessimism over pipeline programs.

Now what

Analyst upgrades and downgrades can be helpful in terms of providing individual investors with a glimpse of how Wall Street thinks about a particular company or stock, but they mean relatively little at the end of the day. 

The direction of the stock will ultimately be determined by clinical outcomes. Nektar Therapeutics exited June 2019 with $1.5 billion in cash, which means it should have adequate funding to develop its lead drug candidates. But the company also burned $134 million in cash in the first six months of the year, so the pressure is on to deliver. 

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nektar Therapeutics Stock Quote
Nektar Therapeutics
$4.91 (-4.47%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.